Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$67.3M Sell
999,563
-124,771
-11% -$8.31M 0.01% 626
2026
Q1
$70.6M Sell
1,124,334
-215,122
-16% -$15M 0.02% 614
2025
Q4
$88.9M Sell
1,339,456
-229,025
-15% -$14.8M 0.02% 547
2025
Q3
$106M Buy
1,568,481
+118,547
+8% +$9.38M 0.02% 475
2025
Q2
$127M Buy
1,449,934
+870
+0.1% +$68.2K 0.03% 396
2025
Q1
$99M Buy
1,449,064
+179,978
+14% +$14.7M 0.03% 423
2024
Q4
$98.7M Buy
1,269,086
+63,240
+5% +$4.68M 0.03% 411
2024
Q3
$80.8M Sell
1,205,846
-249,627
-17% -$20.5M 0.02% 506
2024
Q2
$165M Buy
1,455,473
+174,646
+14% +$22.1M 0.05% 270
2024
Q1
$178M Buy
1,280,827
+170,755
+15% +$21.5M 0.06% 253
2023
Q4
$138M Buy
1,110,072
+88,500
+9% +$9.04M 0.05% 319
2023
Q3
$95.3M Buy
1,021,572
+226,783
+29% +$25.6M 0.06% 324
2023
Q2
$102M Buy
794,789
+374,840
+89% +$45.3M 0.06% 269
2023
Q1
$48.8M Sell
419,949
-173,975
-29% -$19.5M 0.02% 473
2022
Q4
$67.3M Buy
593,924
+141,639
+31% +$15.6M 0.03% 369
2022
Q3
$36.4M Buy
452,285
+73,084
+19% +$6.19M 0.04% 404
2022
Q2
$28.3M Sell
379,201
-228,983
-38% -$20.9M 0.02% 577
2022
Q1
$77.8M Sell
608,184
-159,992
-21% -$17.5M 0.06% 293
2021
Q4
$103M Buy
768,176
+13,080
+2% +$1.88M 0.04% 339
2021
Q3
$103M Buy
755,096
+163,936
+28% +$20.7M 0.05% 308
2021
Q2
$63.1M Buy
591,160
+61,724
+12% +$5.93M 0.03% 427
2021
Q1
$47.6M Sell
529,436
-146,924
-22% -$13.8M 0.03% 466
2020
Q4
$62.5M Buy
676,360
+197,940
+41% +$17.7M 0.03% 389
2020
Q3
$49.3M Buy
478,420
+104,908
+28% +$11M 0.03% 400
2020
Q2
$37.9M Buy
373,512
+244,224
+189% +$21.8M 0.03% 404
2020
Q1
$8.7M Sell
129,288
-9,452
-7% -$588K 0.01% 1077
2019
Q4
$7.59M Sell
138,740
-16,244
-10% -$770K ﹤0.01% 1607
2019
Q3
$5.78M Sell
154,984
-1,009,716
-87% -$39.2M ﹤0.01% 1719
2019
Q2
$43.6M Buy
1,164,700
+1,000,392
+609% +$31.4M 0.03% 536
2019
Q1
$4.89M Sell
164,308
-21,060
-11% -$740K ﹤0.01% 1680
2018
Q4
$5.55M Sell
185,368
-77,340
-29% -$2.45M ﹤0.01% 1522
2018
Q3
$9.39M Buy
262,708
+36,512
+16% +$1.13M 0.01% 1302
2018
Q2
$5.37M Buy
226,196
+156,892
+226% +$3.33M ﹤0.01% 1670
2018
Q1
$1.28M Sell
69,304
-40,660
-37% -$601K ﹤0.01% 2922
2017
Q4
$1.58M Buy
109,964
+76,540
+229% +$995K ﹤0.01% 2667
2017
Q3
$409K Sell
33,424
-49,432
-60% -$874K ﹤0.01% 3808
2017
Q2
$1.51M Buy
82,856
+32,104
+63% +$593K ﹤0.01% 2500
2017
Q1
$1.07M Sell
50,752
-72,116
-59% -$1.41M ﹤0.01% 2667
2016
Q4
$1.83M Buy
122,868
+86,064
+234% +$1.52M ﹤0.01% 2201
2016
Q3
$806K Sell
36,804
-52,828
-59% -$1.18M ﹤0.01% 2827
2016
Q2
$1.78M Buy
89,632
+72,956
+437% +$1.24M ﹤0.01% 2113
2016
Q1
$279K Sell
16,676
-30,984
-65% -$518K ﹤0.01% 3607
2015
Q4
$965K Buy
47,660
+21,924
+85% +$456K ﹤0.01% 2644
2015
Q3
$547K Buy
25,736
+20,692
+410% +$462K ﹤0.01% 3272
2015
Q2
$100K Sell
5,044
-3,956
-44% -$69.5K ﹤0.01% 4670
2015
Q1
$140K Sell
9,000
-212,344
-96% -$3.21M ﹤0.01% 4609
2014
Q4
$3.04M Buy
221,344
+210,972
+2,034% +$2.58M ﹤0.01% 2150
2014
Q3
$101K Buy
10,372
+2,084
+25% +$21.3K ﹤0.01% 5314
2014
Q2
$80K Sell
8,288
-3,708
-31% -$32.9K ﹤0.01% 5587
2014
Q1
$122K Sell
11,996
-44,824
-79% -$463K ﹤0.01% 5266
2013
Q4
$498K Buy
56,820
+13,080
+30% +$104K ﹤0.01% 4100
2013
Q3
$306K Buy
43,740
+28,704
+191% +$182K ﹤0.01% 4614
2013
Q2
$84K Buy
+15,036
New +$72K ﹤0.01% 5918

Other funds holding DXCM

Barclays's DXCM Position: Q2 2026 in Review

Barclays reduced its DexCom (DXCM) stake by 11% in Q2 2026, selling an estimated $8.31M and leaving 999,563 shares worth $67.3M. The position accounts for 0.01% of the portfolio, ranked #626.

Barclays first reported a position in DXCM in Q2 2013 and has held it in 53 quarters since. The position peaked at $178M in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Barclays held 999,563 shares of DexCom worth $67.3M as of Q2 2026.
  • Barclays sold 124,771 DexCom shares in Q2 2026, an estimated $8.31M.
  • DexCom made up 0.01% of Barclays's portfolio in Q2 2026, its #626 holding.
  • Barclays first reported a position in DexCom in Q2 2013 and has held it in 53 quarters since.
  • Barclays's DexCom position peaked at $178M in Q1 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.